Podcasts about restore vision

Revolutionary €8 Million EU-Funded Project Aims to Restore Vision for Millions with Cutting-Edge Bioprinting Technology to tackle Corneal Blindness A groundbreaking initiative is set to transform the future of vision restoration with the launch of KeratOPrinter, an €8 million EU-funded project pioneering an advanced bioprinting suite capable of producing fully functional, biocompatible, full-thickness human corneas. A Global Solution to Corneal Blindness Corneal blindness is the third leading cause of blindness worldwide, affecting millions of people. Yet, due to an alarming shortage of donor tissue, many patients remain unable to access life-changing corneal transplants. The KeratOPrinter project is tackling this urgent healthcare challenge by developing an innovative 3D bioprinting technology that can replicate the complex structure and functionality of the human cornea - bringing hope to millions in need. Why KeratOPrinter is a Game-Changer Bridging the Global Cornea Shortage: By bioprinting full-thickness, optomechanicallyfunctional corneas, this project has the potential to revolutionize the field of ophthalmology, offering an alternative to limited donor tissues. Real-World Clinical Application: The project integrates Good Manufacturing Practice (GMP)-compliant workflows and AI-driven quality control mechanisms to ensure consistency, reliability, and safe clinical translation. Economic and Societal Impact: By delivering a scalable, cost-effective solution to corneal transplantation, KeratOPrinter will lower production costs, improve access to treatment, and enhance the quality of life for millions, particularly in vulnerable populations. A European Collaboration Driving Innovation The KeratOPrinter project brings together a powerhouse consortium of nine partners from five EU countries - Finland, Germany, Spain, the Netherlands, and Ireland. This multidisciplinary collaboration includes leading research institutes, small and medium-sized enterprises (SMEs), and industry specialists in stem cell differentiation, biomaterials, bioprinter devices, regulatory affairs, and clinical ophthalmology. The project also features state-of-the-art transport solutions, including portable incubators with active CO? and temperature control, ensuring the safe delivery of living cells and biological samples under optimal conditions. Expert Insights: A Visionary Approach to Bioprinting Professor Heli Skottman, KeratOPrinter coordinator from the Faculty of Medicine and Health Technology at Tampere University, Finland, highlights the significance of this initiative: "The KeratOPrinter project has strategically assembled a world-class consortium to develop an innovative bioprinting technology capable of producing standardized, biocompatible, and hypoimmunogenic full-thickness corneas in a scalable, GMP-compliant manner." She further adds: "Corneal blindness is driven by a wide spectrum of ophthalmic conditions requiring corneal transplants. However, the severe global shortage of donor tissue is a major barrier to effective treatment. The KeratOPrinter project presents a revolutionary solution, using cutting-edge technology to address this critical medical challenge." A Bold Step Towards Restoring Vision By harnessing the power of advanced bioprinting technology, the KeratOPrinter project is set to redefine corneal transplantation, making vision-restoring therapy more accessible, efficient, and sustainable. With its transformative impact on ophthalmology, this project marks a new era in regenerative medicine. About KeratOPrinter KeratOPrinter is an EU-funded research project dedicated to developing cutting-edge bioprinting solutions for corneal transplantation. By combining expertise from multiple disciplines, the project aims to produce a scalable, clinically viable solution to address the global challenge of corneal blindness. For more information about the KeratOPrinter project and its initiatives, visit the official project website at htt...

Life can easily become overwhelming with all of its twists and turns, which can take the form of career choices, financial struggles, family dramas, etc.When the path ahead isn't clear, and you don't know what tomorrow holds, it's understandable to feel aimless. During these times, we have to make life-altering decisions and are tempted to give up.If you relate to any of that, then you're in the right place. By the end of this, I pray you'll have a new clarity on life and some actionable things to take and apply.__Follow us on Instagram: @theflow.podcast Subscribe on Youtube: @jchart4__Share this episode with someone that you think it will bless.

Dr. Calvin Roberts, M.D. is Program Manager at the Advanced Research Projects Agency for Health (ARPA-H) where manages for the Transplantation of Human Eye Allografts ( THEA - https://arpa-h.gov/research-and-funding/programs/thea ) program, which aims to transplant whole human eyes to restore vision in patients who are blind or visually impaired by reconnecting the nerves, muscles and blood vessels of whole donor eyes to the brain. Dr. Roberts joined ARPA-H in September 2023 from Lighthouse Guild International, where is the president and chief executive officer. Lighthouse Guild is a not-for-profit organization that provides programs and services to people who are blind or visually impaired. Previously, Dr. Roberts was the chief medical officer for the global eye care company Bausch + Lomb. For the past 40 years, Roberts has also served as a clinical professor of ophthalmology at Weill Cornell Medical Center. As a practicing ophthalmologist from 1982 to 2008, he performed more than 10,000 cataract surgeries, as well as 5,000 refractive and other corneal surgeries. He is credited with developing surgical therapies, over-the-counter products for vision care, prescription ocular therapeutics and innovative treatment regimens. He also holds patents on the wide-field specular microscope and has done extensive research on ophthalmic non-steroidals and post-operative cystoid macular edema. Dr. Roberts also hosts the podcast series “On Tech and Vision” ( https://lighthouseguild.org/technology/on-tech-and-vision-podcast/ ) – where innovators discuss how rapidly evolving assistive technology creates equity among those who are visually impaired. Dr. Roberts received his medical degree from Columbia University, completed an internship and ophthalmology residency at New York Presbyterian Hospital, and conducted cornea fellowships at Massachusetts Eye and Infirmary and the Schepens Eye Institute. Support the show

We want to help you conquer your vision loss. Find out more about Dr.Kondrot's Restore Vision program. www.kondrotprogram.com

What are you doing with the light you've been given? Do you let it illuminate areas of darkness or hide it? Do you use it as a weapon to condemn those in darkness, or as a lamp to illuminate their path back to God? We have the unique opportunity to help those lost and stumbling in darkness find their way back home into the loving arms of a gracious God through the work of Jesus Christ. The question is, what are we doing with that opportunity?

Episode 22. A conversation with Prof Thomas Ritter who, with his team in University of Galway, is embarking on a journey of advancing treatments for rare eye diseases in Europe. Restore Vision is a project funded by the European Commission aiming to develop and test new treatments for 7 rare eye diseases (REDs). The consortium joins 10 European key players on rare eye diseases and is led by University of Galway. With 25+ years of experience in immunology and gene therapies for eye diseases, Prof. Ritter's research focuses on novel gene and cell therapies. He earned his Ph.D. in 1994 from the University of Erlangen-Nuremberg, Germany, and completed his Post-Doctoral Fellowship at the Marseille Center of Immunology in 1995. At Charité University Hospital in Berlin, Germany, Prof. Ritter led the gene therapy program in experimental transplantation under Prof. Volk's directorship. He obtained significant funding from the German Research Foundation, Ministry of Health and Research, and industry (Schering). In 2002, he completed his ‘Habilitation' in Immunology, becoming an assistant professor in 2003. Since joining the University of Galway in 2005, Prof. Ritter secured significant funding from various agencies, totaling approximately €7M. He has published 90+ research articles and 30 reviews in peer-reviewed journals, delivered 50+ invited lectures, and served as Vice-Dean for Research at NUI Galway. He is an Associate Editor for Molecular Therapy, serves as a referee for high-impact journals, and is involved in multiple European networks for Cooperation in Science and Technology (COST-Action). For more information visit: https://restorevision-project.eu https://www.aniridia.eu  

What happens when a vision researcher has a chance meeting with a pediatric oncologist and that collaboration leads to unexpected and promising results?In Episode 5 of Your Complex Brain, we're talking about a homegrown vision rehabilitation program helping young brain cancer survivors, whose sight has been impacted by their tumours, improve their vision.The program, developed at University Health Network in Toronto, uses virtual reality to effectively retrain parts of the brain, allowing them to better perceive objects and obstacles.Joining us on the podcast today is neurobiologist, Dr. Michael Reber, and pediatric oncologist, Dr. Eric Bouffet. We'll also hear from 18 year-old Jack Conway, one of the research participants in the study.Featuring: Dr. Michael Reber - Senior Scientist at the Donald K. Johnson Eye Institute, part of the Krembil Research Institute, at University Health Network, and Associate Professor in the Department of Ophthalmology and Vision Sciences at the University of Toronto.Dr. Eric Bouffet - Past director of the Pediatric Neuro-Oncology program at the Hospital for Sick Children in Toronto, and the first Garron Family Chair in Childhood Cancer Research.Jack Conway - High school student who is passionate about video games, theme parks, and politics. Jack was diagnosed with an optic pathway glioma brain tumour as an infant, and recently was a research participant in the Vision Rehab Study.Additional resources: Donald K. Johnson Eye Institute at UHNDr. Reber's lab websiteThe Hospital for Sick ChildrenUHN Foundation story on this Vision Rehab StudyDr. Reber interviewed on UHN's ‘Behind the Breakthrough' podcastDr. Bouffet addresses United NationsThe Krembil Brain Institute, part of University Health Network, in Toronto, is home to one of the world's largest and most comprehensive teams of physicians and scientists uniquely working hand-in-hand to prevent and confront problems of the brain and spine, such as Parkinson's, Alzheimer's, epilepsy, stroke, spinal cord injury, chronic pain, brain cancer or concussion, in their lifetime. Through state-of-the-art patient care and advanced research, we are working relentlessly toward finding new treatments and cures.Do you want to know more about the Krembil Brain Institute at UHN? Visit us at: uhn.ca/krembilTo get in touch, email us at krembil@uhnresearch.ca or message us on social media:Instagram - @krembilresearchTwitter - @KBI_UHNFacebook - https://www.facebook.com/KrembilBrainInstituteThanks for listening!

Bugging Battle Brings Bold Beginnings for Australian Mobile Networks. A Third of Adults Encounter Excessive Noise Exposure.  Australian Advertising Abuses Abound as Influencers Incite ACCC Ire.  Frugal Food Franchises Flock to Future-Forward Furnace.  Apple and Google Grapple With AirTag Stalking.  Spectacular Specs Selectively Subdue Scintillation.  Australian Electric Vehicle Uptake Lags Behind Global Pace.  Bionic Eye Seeks to Restore Vision for the Blind.  LG's Latest Luxury in Fantastically Flexible Display. 

Restoring vision for the visually impaired has been a dream of scientists and clinicians for centuries. Neurodegenerative eye diseases like glaucoma or age-related macular degeneration affect visual information processing.  But the visual system in humans is smart–it can compensate for a loss in connectivity caused by disease. The potential for virtual reality cognitive retraining may improve the quality of life in visually impaired individuals. These retraining devices are effortlessly portable; therefore, protocols can be completed from the comfort of someone's home.

Support this podcast at — https://redcircle.com/hypnosis-and-relaxation-sound-therapy9715/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Pharmacological approaches to longevity using drugs like rapamycin and Acarbose via targeting signaling molecules like mTOR and insulin continue to see growing support. Today we speak with Bradley S Rosen MD whose practice focuses on Living Healthier and Longer through Biogerontology. Dr Rosen graduated with a degree in Mathematics and Statistics and an MD from the University of Florida. His residency was at Jules Stein Eye Institute at UCLA, followed by 2 Retina Fellowships at the Lions Eye Institute and the Royal Victorian Eye and Ear Hospital in Melbourne, Australia. In 2013 Dr. Rosen, M.D. joined a growing number of scientists and clinicians who are becoming increasingly interested in the fact that the hallmarks of aging themselves can and should be targeted for therapy.https://mtormd.com/ @DrBradleyRosen1Lu, Yuancheng, Benedikt Brommer, Xiao Tian, Anitha Krishnan, Margarita Meer, Chen Wang, Daniel L. Vera, et al. “Reprogramming to Recover Youthful Epigenetic Information and Restore Vision.” Nature 588, no. 7836 (December 3, 2020): 124–29. https://doi.org/10.1038/s41586-020-2975-4.Jiang, Zhou, Juan Wang, Denise Imai, Tim Snider, Jenna Klug, Ruby Mangalindan, John Morton, et al. “Short Term Treatment with a Cocktail of Rapamycin, Acarbose and Phenylbutyrate Delays Aging Phenotypes in Mice.” Scientific Reports 12, no. 1 (December 2022): 7300. https://doi.org/10.1038/s41598-022-11229-1.https://www.nature.com/articles/s41598-022-11229-1 *** CONNECT WITH ROBERT LUFKIN MD ON SOCIAL MEDIA ***Web: https://robertlufkinmd.com/ Twitter:https://twitter.com/robertlufkinmdYoutube: https://www.youtube.com/RobertLufkinMD*** MEMBERSHIP ***https://robert-lufkin.mykajabi.com/membership *** SPONSORSHIPS & BRANDS ***We do work with sponsors and brands. If you are interested in working with us for your health industry product or service, please contact us at: https://robertlufkinmd.com/contact  NOTE: This is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have. Never disregard professional medical advice or delay in seeking it because of something you have seen here. Robert Lufkin MD may at any time and at its sole discretion change or replace the information available on this channel. To the extent permitted by mandatory law, Robert Lufkin MD shall not be liable for any direct, incidental, consequential, indirect or punitive damages arising out of access to or use of any content available on this channel, including viruses, regardless of the accuracy or completeness of any such content.Disclaimer: We are ambassadors or affiliates for many of the brands we reference on the channel.Support the show

Following on from the recent news about a lady in her 80's who has dry Age Related Macular degeneration who has just been given a bionic eye implant as part of a Europe wide clinical trial developed by Pixium Vision in France along with Consultants from Moorfields Eye Hospital here in the UK. Connect Radio's Toby Davey chats with Mahi Muqit, the Eye Consultant from Moorfields Eye Hospital, who implanted the bionic chip into 'Bionic Nana' as her Grandchildren call her to find out more about the technology behind the clinical medical trial of this bionic eye chip implant. Mahi began by giving Toby a bit of background to the clinical medical trial and how the technology works. Mahi then talked about how in the future the bionic eye chip implant could be very beneficial to other people like Bionic Nana who have dry Age Related Macular Degeneration which is currently not able to be treated with injections like wet AMD.     Mahi ended by stating that the technology and the clinical medical trial is very much in the early stages however, there is hope for the future. More details about the clinical medical bionic eye chip implant can be found by visiting the following article on Moorfields website - https://www.moorfields.nhs.uk/news/revolutionary-bionic-chip-inserted-moorfields-patient-s-blind-eye   (Image shows RNIB logo. 'RNIB' written in black capital letters over a white background and underlined with a bold pink line, with the words 'See differently' underneath)

Reversing DNA methylation can result in restoration of vision loss in old mice (Lu 2020).  Can human epigenetic methylation clocks be reversed using relatively straightforward lifestyle changes?  Dr Kara Fitzgerald  is on the faculty at the Institute for Functional Medicine (IFM) and is an IFM Certified Practitioner. She received her doctorate in naturopathic medicine from the National College of Naturopathic Medicine in Portland, Oregon. Dr. Fitzgerald runs a Functional Medicine Clinic Immersion program for professionals, hosts a very popular podcast New Frontiers in Functional Medicine, and maintains an active blog on her website.  Her new book 'Younger You' is coming out in Jan 2022.  Please join Dr Kara Fitzgerald for this masterclass in human epigenetic DNA methylation manipulation.Take away points: -Increased DNA methylation age is associated with no significant net methylation change.-~25% of methylation clock sites are related to glucocorticoid response elements underscoring the relationship of stress and aging.—Supplemental methylation helpers (folate, b12, choline, etc) have a narrow effective range- with too little or too much having negative consequences.-Lifestyle changes can reverse DNA methylation age in humans.00:00 Kara's vision for reversing global epidemic of chronic disease03:10 Appeal of naturopathic medicine as a systems model similar to functional medicine 06:04 Value of -omics; epigenomics, metabolomics, and microbiomics07:39 DNA methylation process and epigenetic age11:39 No net change in methylation with aging, just rearrangement of sites12:25 Dose response of dietary methyl donors15:18 Horvath methylation clock used in paper19:23 Components of the lifestyle intervention 25:32 Effect on triglycerides28:34 Options for vegans instead of liver as a methyl donor32:05 Ongoing program and forthcoming book35:05 Personal lifestyle choices37:02 10 cups of vegetables a day, 12 hour fast per day 38:03 Exercise, relaxation, and sleep choices  https://www.drkarafitzgerald.com/ Lu, Yuancheng, Benedikt Brommer, Xiao Tian, Anitha Krishnan, Margarita Meer, Chen Wang, Daniel L. Vera, et al. “Reprogramming to Recover Youthful Epigenetic Information and Restore Vision.” Nature 588, no. 7836 (December 3, 2020): 124–29. https://doi.org/10.1038/s41586-020-2975-4. Fitzgerald, Kara N., Romilly Hodges, Douglas Hanes, Emily Stack, David Cheishvili, Moshe Szyf, Janine Henkel, et al. “Potential Reversal of Epigenetic Age Using a Diet and Lifestyle Intervention: A Pilot Randomized Clinical Trial.” Aging 13, no. 7 (April 15, 2021): 9419–32. https://doi.org/10.18632/aging.202913.*** SUBSCRIBE TO ROBERT LUFKIN MD YOUTUBE CHANNEL HERE ***https://www.youtube.com/channel/UC2w2eKHmcRXuGR8RmTgUv3Q*** CONNECT WITH ROBERT LUFKIN MD ON SOCIAL MEDIA ***Web: https://robertlufkinmd.com/Twitter:https://twitter.com/robertlufkinmdNOTE: This is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have. Never disregard professional medical advice or delay in seeking it because of something you have seen here.Disclaimer: We are ambassadors or affiliates for many of the brands we reference on the channel. ------------------------------------------------------------------------#longevity  #wellness #antiaging #biologicalage #lifestylemedicine #younger #epigenetics #biohacking  #RobertLufkinMD #Karafitzgerald

Andrea Macdonald founder ideaXme interviews Dr Pieter Roelfsema Director Netherlands Institute for Neuroscience. Andrea Macdonald founder ideaXme: [00:06:52] Welcome everybody again to another episode of the ideaXme show. I'm Andrea Macdonald, the founder of ideaXme. ideaXme is a global podcast available in 40 countries worldwide, a creator series and mentor program.   [00:07:10] This episode concerns itself with a breakthrough towards developing a technology to restore functional vision to the blind. I'm here with the director of the Netherlands Institute for Neuroscience (NIN). Who are you?   Pieter Roelfsema Director NIN: [00:07:29] My name is Pieter Roelfsema. I studied medicine but if you feel ill, you don't want me beside your bed. I went into science, studied the visual system. Few years ago, we thought: “Why not use knowledge all that knowledge we have accumulated. Why don't we start thinking about creating a device that restores rudimentary form of vision for blind people?”.   Andrea Macdonald founder ideaXme: [00:07:54] There are over 40 million blind people worldwide, over two billion visually impaired, over one billion visually impaired, where this impairment could have been avoided. Could you explain the process through which a human being receives vision, or a non-visually impaired human being receives vision to the brain where it is perceived as such?   Pieter Roelfsema Director NIN: [00:08:28] So the information that comes into your eyes is a sharp image on the back of your eye where your retina is. Then the information from the retina is sent through the optic nerve to a region in the mid brain called the thalamus. And from there it's sent on to the back of our brain. There's a region that's called primary visual cortex, and that region has a very accurate, two-dimensional representation of the outside world, where two points that are nearby in the outside world will map onto two points in your brain that are also nearby. So, it's a very systematic map of the outside world.   Andrea Macdonald founder ideaXme: [00:09:11] And could you talk a little bit about the solution that you are providing and how it doesn't actually deal with addressing issues in the eye it deals with addressing issues in the brain or the back of the brain in the visual cortex?   Pieter Roelfsema Director NIN: [00:09:34] What we know from previous work is that if you put an electrode in that region that I was just alluding to, the primary visual cortex, then you can put a little bit of current on it and you can stimulate the nerve cells that are nearby. An electrode is just a wire, actually. And so, these nerve cells will become active and a person, this can also be a person who has been blind for several years, will perceive a dot of light at that location that corresponds to the position of these two-dimensional map I was talking about. So, if you then stimulate with another wire, an electrode that is nearby, this person will see a dot of light that is close to the first dot of light. If you then have a whole series of wires, a whole series of electrodes, then you basically are addressing a part of the map and you can place dots in the person's perception at many, many different locations and you can work with it like a matrix board. So, if I'm going to stimulate one electrode, you're going to see a lot of light. But if you stimulate like in a matrix board if you switch on a single bulb you will see a dot. But on a matrix board you can also switch on several bulbs in the shape of a letter or convey other meaningful information. And we could do the same thing if you have many electrodes in the visual cortex, you can just switch on dot perceptions at many different locations and thereby convey meaningful information. Now, if a person would have such a prosthesis, which still needs to be developed further, this person would carry a camera. It could be embedded in glasses, then that kind of camera image will be sent to a processor, maybe the size of a phone that translates these camera images into brain stimulation patterns that are then going to be sent to those electrodes, maybe wirelessly.   Pieter Roelfsema Director NIN: [00:11:27] So that's something also that needs to be developed. So, right now, the brain computer interfaces, many of them, they actually have a wire coming out of the skull to make the connection to the brain. Now, of course, in the future, a device that is safe and that can be used easily one would like all these things to be completely wireless.   Andrea Macdonald founder ideaXme: [00:11:48] Work in this area first started in the 1970s. Could you explain to the audience why the research that you head up represents such a breakthrough?   Pieter Roelfsema Director NIN: [00:12:02] Yes, so there was a fantastic researcher in the U.K., his name was Giles Brindley, he was already doing this in the 60s and in the early 70s. It's really remarkable because he already made a system that was wireless.   Pieter Roelfsema Director NIN: [00:12:17] So basically, he had small coils, small kind of wire coils under the skin. Several of them actually more than one hundred.   Pieter Roelfsema Director NIN: [00:12:26] And he then used a coil on the outside to induce current in a coil under the skin and then he ran a wire to the visual cortex and was able to stimulate brain cells. It was amazing that he could already do this back then, of course, we are now 50 years later, and we have improved technology, so our game is easier. We have better ways to interface with the brain, actually back then, he also put electrodes on the surface of the brain. We have found out that you can get perception's with less current if you have electrodes inside the brain. And that's an advantage. We have actually one thousand electrodes in the experiment that we recently did in monkeys. And so, we have basically more pixels from which we can build a mental image. And of course, there are other advances now. So, it's better electrode technology. We have now wireless chips that can, of course, digest much more information. So, I think this is the right time to make to make this happen.   Andrea Macdonald founder ideaXme: [00:13:33] Could you explain a little bit about how the eBrains 3D Brain Atlas has helped you to advance this research?   Pieter Roelfsema Director NIN: [00:13:45] Yes. So eBrains is part of The Human Brain Project. It is a collection of services that The Human Brain Project or its successor will offer to the neuroscience community. Now, for our research, we have to kind of take the shape of this visual cortex where we want to implant electrodes into account. The shape of the visual cortex is complicated. It has all kinds of folds. We call them sulci. And they are different from one individual to another, so we need to devise a strategy to implant electrodes, a sufficient number of electrodes, we're thinking about thousands of electrodes and we want to make sure that most of them are positioned in the right location. And that's where eBrains is tremendously helpful because they have the anatomical knowledge, and they can also provide some of the tools that allow us to do the correct mapping.   Andrea Macdonald founder ideaXme: [00:14:42] And you have mentioned in your paper that there are a number of issues that remain to be addressed.   Andrea Macdonald founder ideaXme: [00:14:52] And you've been very open about the fact that once this represents a breakthrough, you know, a lot more work needs to be done in this area. A couple of things you mentioned were a certain specific form of WIFI system needs to be developed. And you also mentioned that the whole area of tissue damage needs to be addressed. Could you talk about those two things, please?   Pieter Roelfsema Director NIN: [00:15:21] Yes. The electrodes are right now using they are stiff silicon electrodes.   Pieter Roelfsema Director NIN: [00:15:27] There is a mechanical mismatch between the brain tissue, which is soft and the stiff rods. And the impression has been, although this is not very well documented, is that this mismatch in mechanical properties caused this kind of sort of sliding between the electrodes and the brain tissue that then results in the build-up of tissue, glial tissue, sort of fibrous tissue that pushes the nerve cells away from the electrodes and thereby making it more difficult to stimulate the neurons. So, one way to go that seems promising is to use other materials that are much softer. So, one of them is Polyimide, which is sort of a plastic, which you can make very thin wires. And they seem then to be causing less damage than those silicon rods.   Pieter Roelfsema Director NIN: [00:16:22] So that's one area where developments are currently taking place that look quite promising. The other point that you asked me to reflect upon is wireless systems. So also, there is tremendous developments there. There are systems that allow researchers to communicate with the brain, putting something under the skin and something above the skin that has enough bandwidth basically to allow communication at a high enough rate to make that possible. But also, there are definitely some developments to be further taken.   Andrea Macdonald founder ideaXme: [00:17:05] And the recent research that you've spoken about in your paper, I believe, has focused on using animals to test this technology. At what point, although I know that similar technologies have also been tested in humans, when do you see the earliest time that you can transition from animals to humans?   Andrea Macdonald founder ideaXme: [00:17:28] Because, of course, there are many movements in the world that are against animal testing and whether it causes pain or not. There’s a great deal of discomfort about it. I'm just wondering what the plans are to transition this to humans?   Pieter Roelfsema Director NIN: [00:17:50] It would not be ethical to just do this in humans and just hope for the best. So, most people I talk to think that you first have to thoroughly test this. And some of this testing involves animals. And in this particular research, we had to use monkeys because they are the closest to humans and in monkeys, we could really test whether if you stimulate a pattern of electrodes in the visual cortex, they could recognize that as a pattern. This could not have been done in another species. Now, in collaboration and actually mainly driven by researchers in Spain, Eduardo Fernandez, who is also a co-author on our paper, we actually tested the same approach already in one human patients. There was an MIT Tech Review about it recently. And the good news is that many of these same stimulation patterns that we tried in monkeys also appeared to work in this in this particular individual. So, we're actually already making this step. But if you want to use other electrode materials and also wireless chips, again, we first have to demonstrate that they can be used safely. And some of these things you can test without animals. But some of these tests really involve animals. And it's even the legal requirement to demonstrate that this works in animals first. And I think that's also only the only ethical way to do it. You cannot just put something in a human and hope for the best.   Andrea Macdonald founder ideaXme: [00:19:22] And the ideaXme audience is comprised of the general public, future innovators and creators, as well as the actual people who are shaping our world from the space industry right the way through to science, arts and philosophy. It would be really interesting to hear at this point, particularly for future innovators within your sector, to hear a little bit about your human story and your journey to this point. And as far as who maybe sparked your interest in this area and who influenced you and the choices you made along the way to get here.   Pieter Roelfsema Director NIN: [00:20:08] Ok, that's a very broad question. And so, I started studying medicine and at some point, I didn't see myself as a medical doctor. So, I was really interested in science. And then I read a book called Gödel, Escher, Bach: An Eternal Golden Braid, written by Douglas Hofstadter, which was mainly about consciousness. And I thought, this is a really interesting topic that I want to spend time on.  This is what I really would like to do. So then at some point during my studies, I already started to do some neuroscience work just as a volunteer. And then I already applied to do a PhD project with Wolf Singer, Director the Max Planck Research Institute in Frankfurt. He said, well, why don't you first finish your studies? So that's what I did.   Pieter Roelfsema Director NIN: [00:21:04] I went back to the Netherlands or to where I studied, and I completed my studies hoping that he would remember that he said that I would be welcome in his lab after I completed my studies and he had not forgotten. So, I was really pleased to be part of his lab. And he was probably one of the people who influenced me the most. I had a wonderful time doing PhD research in that lab. And after that, I just continued the neuroscience. I did a lot of work just on pure vision, just trying to understand how vision works.   Pieter Roelfsema Director NIN: [00:21:43] Through those studies, I think I started to read also more about prosthetics. Another person that I enjoyed talking to and who influenced me was Jens Neumann. He was one of the people in the program of Bill Dobelle, who also had a visual prosthesis program. And was one of the subjects. He had a cortical implant. It didn't work for very long. He's still a very inspiring person. And talking to him also inspired me to continue in this direction.   Andrea Macdonald founder ideaXme: [00:22:21] Could you talk a little bit about the team that you're currently working with in their various roles in helping move this forward?   Pieter Roelfsema Director NIN: [00:22:29] Yes, so we started this visual cortical prosthesis project, I think, in 2014. Then Xing Chen, who is the first author on the paper, joined the group. And with her, we really started to do this work. We got a lot of help from a company, Blackrock Microsystems, which helped us design the implants and make sure that we could do this for 1000 channels because that had not been done before. And after that, several other people joined the lab, Feng Wang who was also a co-author on the paper. We established contact with Eduardo Fernandez, I have already mentioned him. They're doing this work in Spain. And now the team that works on visual prosthesis is about six people in the lab. And we also started a company, Phosphoenix, because we realized that if you really want to put something in patients, you also need a commercial entity for various regulatory issues.   Andrea Macdonald founder ideaXme: [00:23:29] Pieter Roelfsema, thank you very much for your time and thank you for moving the human story forward. It's been an absolute pleasure.   Pieter Roelfsema Director NIN: [00:23:39] Thanks a lot. My pleasure.   ideaXme is a global network to encourage everyone to learn of the people, issues and ideas that are anticipated to impact our collective futures. As well as a global podcast, ideaXme is a mentor programme, creator series and think tank. Follow us on Twitter @ideaxm Instagram: @ideaxme Connect with us here www.radioideaxme.com    

Go online to PeerView.com/AGK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in choroideremia discusses the diagnosis of choroideremia and treatment via novel and emerging gene therapies. Upon completion of this activity, participants should be better able to: Describe current unmet needs with regard to the treatment of choroideremia and the burden on patient quality of life, Apply evidence-based criteria to recognize and diagnose choroideremia, including the use of genetic testing, Recognize the potential impact of novel and emerging gene therapies on the management of patients with choroideremia, Identify patients who may be eligible for treatment, should therapies become approved, and/or enrollment in clinical trials.

Go online to PeerView.com/AGK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in choroideremia discusses the diagnosis of choroideremia and treatment via novel and emerging gene therapies. Upon completion of this activity, participants should be better able to: Describe current unmet needs with regard to the treatment of choroideremia and the burden on patient quality of life, Apply evidence-based criteria to recognize and diagnose choroideremia, including the use of genetic testing, Recognize the potential impact of novel and emerging gene therapies on the management of patients with choroideremia, Identify patients who may be eligible for treatment, should therapies become approved, and/or enrollment in clinical trials.

Restore Church: Marks Gather weekly, Give sacrificially, Serve intentionally, Walk in community, Pray faithfully, Reconcile swiftly, Proclaim regularly Preacher: Mike Hanafee

Dr. David Gamm receives funding from Fighting Blindness Canada (FBC) to support his stem cell research that aims to develop a sight-restorative therapy. Dr. Gamm is funded through FBC’s Restore Vision 20/20 Initiative. He is an Associate Professor, Ophthalmology and Visual Sciences at the University of Wisconsin-Madison. Dr. Gamm spoke about his work on stem cells at the 2019 Vision Quest in Vancouver.

What you can do to Restore Vision for Jesus

This message by Phil Varley, our Associate Pastor, is part of of our Vision 2030 series, sharing a new vision for King's, a vision not just for the next twelve months, but the next twelve years. The second of our three main themes is RESTORE. The church is a place of restoration. Partly, this is because the Gospel restores people as we become believers and find new purpose, wholeness and life. But it is also because we see things that we cannot simply walk past. There are needs and injustices all around us. Biblical churches restore communities, not just individuals, and if we ever "shut up shop" as a church, the local community should miss us and the positive impact we have on the area. For more information and the Vision 2030 booklet, visit kingschurchlondon.org/vision.

In this week’s VIP, Nelson and James are joined by Allison Sheridan from Podfeet. They discuss the top stories from Cool Blind Tech and give you some Cool Picks to think about. Top Stories Amazon Introduces New Accessibility Features for Blind and Visually Impaired Customers Brain Implant Launching Clinical Trial to Restore Vision to Patients Court Finds That Accessibility Rules Apply to Retail Websites Show links Interview with Second Sight at CSUN Tutorial of Recording Skype with Audio Hijack Soundflower on Github (3 years ago) egrips for iPhone Cool Picks Rogue Amoeba's Audio Hijack iPhone 8 Plus from Apple Facebook on the App Store for iOS.

In this week’s VIP, Nelson and James are joined by Allison Sheridan from Podfeet. They discuss the top stories from Cool Blind Tech and give you some Cool Picks to think about. Top Stories Amazon Introduces New Accessibility Features for Blind and Visually Impaired Customers Brain Implant Launching Clinical Trial to Restore Vision to Patients Court Finds That Accessibility Rules Apply to Retail Websites Show links Interview with Second Sight at CSUN Tutorial of Recording Skype with Audio Hijack Soundflower on Github (3 years ago) egrips for iPhone Cool Picks Rogue Amoeba's Audio Hijack iPhone 8 Plus from Apple Facebook on the App Store for iOS.

A treatment is on the way for stroke survivors who experience difficulty with their vision, says Krystel Huxlin, the James V. Aquavella Professor and Director of Research at the University of Rochester Medical Center’s Flaum Eye Institute. Quadcast host Sandra Knispel talks with the vison expert about repairing and restoring basic vision with the help of a therapy that Huxlin has pioneered.

VISIONMAX, EYE RETINAL CARE, OXIDATIVE EYE PROTECTION, RESTORE VISION, EYE ANTIAGING, CANCER PROSTATE PREVENTION, BENIGN PROSTATE, PROSTATE HEALTH, NUTRIMEDICAL.COM 888-212-8871, DR BILL DEAGLE MD AAEM ACAM A4M